EP4132511A4 - Pharmazeutische zusammensetzungen mit meloxicam - Google Patents
Pharmazeutische zusammensetzungen mit meloxicam Download PDFInfo
- Publication number
- EP4132511A4 EP4132511A4 EP21784898.5A EP21784898A EP4132511A4 EP 4132511 A4 EP4132511 A4 EP 4132511A4 EP 21784898 A EP21784898 A EP 21784898A EP 4132511 A4 EP4132511 A4 EP 4132511A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- meloxicam
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063006023P | 2020-04-06 | 2020-04-06 | |
| US16/841,436 US10821181B2 (en) | 2015-02-10 | 2020-04-06 | Pharmaceutical compositions comprising meloxicam |
| US16/842,063 US10799588B2 (en) | 2015-02-10 | 2020-04-07 | Pharmaceutical compositions comprising meloxicam |
| US16/867,929 US10821182B2 (en) | 2017-06-29 | 2020-05-06 | Pharmaceutical compositions comprising meloxicam |
| PCT/US2021/026027 WO2021207253A1 (en) | 2020-04-06 | 2021-04-06 | Pharmaceutical compositions comprising meloxicam |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4132511A1 EP4132511A1 (de) | 2023-02-15 |
| EP4132511A4 true EP4132511A4 (de) | 2024-05-15 |
Family
ID=78023056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP21784898.5A Pending EP4132511A4 (de) | 2020-04-06 | 2021-04-06 | Pharmazeutische zusammensetzungen mit meloxicam |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4132511A4 (de) |
| JP (1) | JP2023520574A (de) |
| KR (1) | KR20220164557A (de) |
| CN (1) | CN115697326A (de) |
| CA (1) | CA3179681A1 (de) |
| WO (1) | WO2021207253A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12485176B2 (en) | 2015-02-10 | 2025-12-02 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US11617791B2 (en) | 2017-06-29 | 2023-04-04 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US20240058354A1 (en) | 2020-04-06 | 2024-02-22 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US12128052B2 (en) | 2020-05-28 | 2024-10-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| EP4271386A4 (de) | 2020-12-31 | 2024-11-13 | Axsome Therapeutics, Inc. | Pharmazeutische zusammensetzungen mit meloxicam |
| US12370196B2 (en) | 2020-12-31 | 2025-07-29 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US12005118B2 (en) * | 2022-05-19 | 2024-06-11 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US12544383B1 (en) * | 2025-01-30 | 2026-02-10 | Axsome Therapeutics, Inc. | Methods of treating migraines with a combination of a meloxicam and a rizatriptan |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200085954A1 (en) * | 2015-02-10 | 2020-03-19 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2301304A1 (en) * | 1997-08-27 | 1999-03-04 | Hexal Ag | New pharmaceutical compositions of meloxicam with improved solubility and bioavailability |
| EP1744757A4 (de) * | 2004-05-04 | 2009-04-22 | Equitech Corp | Verbesserte nsaid-zusammensetzung |
| WO2014161131A1 (en) * | 2013-04-01 | 2014-10-09 | Arissa Pharma | PREPARING AMORPHOUS MELOXICAM-β-CYCLODEXTRIN INCLUSION COMPLEX VIA SPRAY DRYING PROCESS |
| US10058614B2 (en) * | 2015-02-10 | 2018-08-28 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| US10471014B2 (en) * | 2017-01-04 | 2019-11-12 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
| SI3565550T1 (sl) * | 2017-01-04 | 2021-04-30 | Axsome Therapeutics, Inc. | Farmacevtske sestave, ki vsebujejo meloksikam in rizatriptan |
| EP4467600A3 (de) * | 2017-05-10 | 2025-03-12 | Axsome Therapeutics, Inc. | Pharmazeutische zusammensetzungen mit meloxicam |
| KR102815027B1 (ko) * | 2018-07-03 | 2025-05-30 | 액섬 테라퓨틱스, 인크. | 멜록시캄을 포함하는 약학적 조성물 |
-
2021
- 2021-04-06 EP EP21784898.5A patent/EP4132511A4/de active Pending
- 2021-04-06 JP JP2022560874A patent/JP2023520574A/ja active Pending
- 2021-04-06 KR KR1020227038594A patent/KR20220164557A/ko active Pending
- 2021-04-06 WO PCT/US2021/026027 patent/WO2021207253A1/en not_active Ceased
- 2021-04-06 CN CN202180039884.XA patent/CN115697326A/zh active Pending
- 2021-04-06 CA CA3179681A patent/CA3179681A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200085954A1 (en) * | 2015-02-10 | 2020-03-19 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising meloxicam |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4132511A1 (de) | 2023-02-15 |
| KR20220164557A (ko) | 2022-12-13 |
| CA3179681A1 (en) | 2021-10-14 |
| JP2023520574A (ja) | 2023-05-17 |
| WO2021207253A1 (en) | 2021-10-14 |
| CN115697326A (zh) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3817722A4 (de) | Pharmazeutische zusammensetzungen mit meloxicam | |
| EP4132511A4 (de) | Pharmazeutische zusammensetzungen mit meloxicam | |
| MA55206A (fr) | Polyribonucléotides circulaires et compositions pharmaceutiques associées | |
| EP3565550A4 (de) | Pharmazeutische zusammensetzungen mit meloxicam | |
| EP3621621A4 (de) | Pharmazeutische zusammensetzungen mit meloxicam | |
| EP3914252A4 (de) | Pharmazeutische zusammensetzung von nilotinib | |
| EP3881846A4 (de) | Pharmazeutische zusammensetzung mit parp-inhibitoren | |
| EP3947353A4 (de) | Pharmazeutische zusammensetzungen und kombinationen mit inhibitoren des androgenrezeptors und deren verwendungen | |
| EP4271386A4 (de) | Pharmazeutische zusammensetzungen mit meloxicam | |
| EP3256138A4 (de) | Pharmazeutische zusammensetzungen mit meloxicam | |
| EP3906019C0 (de) | Pharmazeutische zusammensetzungen von furosemid | |
| MA47816A (fr) | Composition pharmaceutique comprenant du sélexipag | |
| MA55015A (fr) | Formulations pharmaceutiques | |
| EP4221690A4 (de) | Pharmazeutische zusammensetzungen | |
| EP4122483A4 (de) | Orale pharmazeutische zusammensetzung | |
| EP3914234A4 (de) | Pharmazeutische zusammensetzungen | |
| EP3946316A4 (de) | Pharmazeutische cannabidiolzusammensetzungen | |
| EP4135699A4 (de) | Pharmazeutische zusammensetzungen | |
| EP3897593A4 (de) | Cannabinoid-formulierungen und pharmazeutische zusammensetzungen | |
| EP4015001A4 (de) | Orale pharmazeutische zusammensetzung | |
| EP4340857A4 (de) | Formulierung mit modifizierter freisetzung mit withanoliden | |
| MA49837A (fr) | Compositions pharmaceutiques | |
| DK3908321T3 (da) | Farmaceutisk sammensætning | |
| EP3790543A4 (de) | Zusammensetzungen und darreichungsformen zur oralen verabreichung | |
| EP3920909A4 (de) | Pharmazeutische zusammensetzungen mit meloxicam |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20221103 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230509 |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40084389 Country of ref document: HK |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031404500 Ipc: A61K0009200000 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20240416 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/24 20060101ALN20240410BHEP Ipc: A61K 47/69 20170101ALI20240410BHEP Ipc: A61P 29/00 20060101ALI20240410BHEP Ipc: A61K 33/10 20060101ALI20240410BHEP Ipc: A61K 31/5415 20060101ALI20240410BHEP Ipc: A61K 31/4196 20060101ALI20240410BHEP Ipc: A61K 31/724 20060101ALI20240410BHEP Ipc: A61K 9/20 20060101AFI20240410BHEP |
|
| RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: AXSOME THERAPEUTICS, INC. |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: TABUTEAU, HERRIOT |